PMID- 20137694
OWN - NLM
STAT- MEDLINE
DCOM- 20100608
LR  - 20131121
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 89
IP  - 34
DP  - 2009 Sep 15
TI  - [Long-term impact on quality of life in patients with gastroesophageal reflux 
      disease after 52-week rabeprazole treatment].
PG  - 2404-7
AB  - OBJECTIVE: To investigate the longitudinal changes in quality of life (QoL) for 
      gastroesophageal reflux disease (GERD) treated with 52-week rabeprazole over a 
      period of 2-3 years. METHODS: A multi-center, open-label and randomized 52-week 
      rabeprazole trial was conducted in 67 eosinophilic esophagitis (EE) and 31 
      non-erosive reflux disease (NERD) patients. The follow-up period is 2-3 years 
      after the treatment. Their QoL were evaluated using SF-36 Health Survey 
      Questionnaire and GERD-HRQL scale. The results were compared with those acquired 
      before and after a 52-week proton pump inhibitor (PPI) treatment. RESULTS: (1) 
      Both EE and NERD patients improved significantly according to GERD-HRQL scale in 
      scores of reflux symptoms as well as overall satisfaction (12.5 vs 3.5, 20.0 vs 
      14.0, both P < 0.01) versus the pre-therapy baseline. (2) Both EE and NERD 
      patients had no significant difference in the scale of GERD-HRQL (2.0 vs 3.5, 5.0 
      vs 4.0, both P > 0.05) and most major domains of SF-36 questionnaire versus the 
      post-therapy baseline (53 +/- 17 vs 61 +/- 17, t = -2.143, P = 0.035). (3) The 
      NERD patients had a higher score of reflux symptoms than the EE patients 
      according to the GERD-HRQL Scale (14.0 vs 3.5, Z = 2.377, P = 0.017), however 
      there were no significant differences between NERD and EE in 8 major domains of 
      SF-36 questionnaire (P > 0.05). CONCLUSION: Long-term and low-dose PPI treatment 
      achieves improvement both in reflux symptoms and QoL in GERD patients and such 
      effects last a long time. At follow-ups, the reflux symptoms of NERD patients are 
      more severe than EE patients. However, the overall QoL has shown little 
      differences between these two subtypes.
FAU - Yang, Xi-lin
AU  - Yang XL
AD  - Department of Gastroenterology, PUMC Hospital, Chinese Academy of Medical 
      Sciences, Peking Union Medical College, Beijing 100730, China.
FAU - Liu, Xiao-hong
AU  - Liu XH
FAU - Ke, Mei-yun
AU  - Ke MY
FAU - Song, Zhi-qiang
AU  - Song ZQ
FAU - Yuan, Yao-zong
AU  - Yuan YZ
FAU - Luo, Jin-yan
AU  - Luo JY
FAU - Hou, Xiao-hua
AU  - Hou XH
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 32828355LL (Rabeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Gastroesophageal Reflux/*drug therapy
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
MH  - Rabeprazole
MH  - Treatment Outcome
EDAT- 2010/02/09 06:00
MHDA- 2010/06/09 06:00
CRDT- 2010/02/09 06:00
PHST- 2010/02/09 06:00 [entrez]
PHST- 2010/02/09 06:00 [pubmed]
PHST- 2010/06/09 06:00 [medline]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2009 Sep 15;89(34):2404-7.